Timothy Thistlethwaite, MD
Psychiatry · Charleston, WVNPI 1831284116
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations.
Across 43 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$156
- Axsome Therapeutics, Inc.$117
- Lundbeck LLC$84
- Takeda Pharmaceuticals U.S.A., Inc.$74
- Johnson & Johnson$70
- Alkermes, Inc.$68
- plus $204 from 8 others
What the payments were for
- Food & beverage$773100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 8 | $156 |
| Axsome Therapeutics, Inc. | 6 | $117 |
| Lundbeck LLC | 5 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Johnson & Johnson | 3 | $70 |
| Alkermes, Inc. | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Indivior Inc. | 1 | $14 |
How this compares
$773 in reported general payments places this provider in the 70th percentile of 177 psychiatry providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 25 | $5,458 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 139 | $4,437 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $4,107 |
| Bupropion XlBupropion Hcl | 211 | $3,295 |
| Duloxetine Hcl | 172 | $3,127 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 175 | $2,535 |
| Alprazolam | 421 | $2,124 |
| Tranylcypromine Sulfate | 11 | $1,923 |
| Lamotrigine | 156 | $1,765 |
| Vilazodone Hcl | 23 | $1,696 |
| Clonazepam | 186 | $1,668 |
| Aripiprazole | 71 | $1,485 |
| Bupropion Hcl SrBupropion Hcl | 62 | $1,390 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 28 | $1,281 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $1,263 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Charleston
- Melissa MoodyCharleston$1.2M
- Fahd MousaCharleston$200K
- Lawrence KellyCharleston$41K
- Sidney LerfaldCharleston$14K
- Kiran DevarajCharleston$9K
- Krista RhodesCharleston$4K
- Veena BhanotCharleston$833
- Nohl BraunCharleston$612
- April BaisdenScott Depot$775K
- Ryan WakimWheeling$772K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.